课题基金 / 基金详情

Comparative safety of aflibercept and ranibizumab in the treatment of retinal diseases

Comparative safety of aflibercept and ranibizumab in the treatment of retinal diseases
阿柏西普与雷珠单抗治疗视网膜疾病的安全性比较
批准号：
345673
负责人：
Campbell Robert J
金额：
$8.01万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-03-01 至 2019-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=345673&lang=en
关键词：
Aflibercept Comparative Safety Drug Safety Health Services Research Ophthalmology Ranibizumab Retinal Diseases

项目摘要

项目成果

Campbell Robert J的其他基金

相似基金

相关文献

中文摘要
翻译
加拿大失明的经济负担估计为每年158亿美元。 视网膜相关性黄斑变性（ARMD）和糖尿病视网膜病变（DR）分别是加拿大总体和工作年龄人群失明的主要原因。Outc
英文摘要
The economic burden of blindness in Canada is estimated at $15.8 billion annually. Age-related macular degeneration (ARMD) and diabetic retinopathy (DR) are the leading causes of blindness in Canada overall and among working age people respectively. Outc
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Comparative effectiveness of newer oral diabetes medications in preventing advanced diabetic retinopathy
Cardiovascular and Ocular Adverse Events Associated with New Treatments for Age-Related Macular Degeneration
海外基金